Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine - PubMed
- ️Wed Jan 01 2003
Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine
Patrick Olin et al. Vaccine. 2003.
Abstract
Acellular pertussis vaccines were introduced nation-wide in Sweden in 1996, 17 years after the withdrawal of whole-cell pertussis vaccine from the childhood immunisation schedule. We report national data on age specific incidence of culture-confirmed Bordetella pertussis for 1986-2000, and clinical follow-up for 3 years (October 1997-September 2000) in children born in 1996-2000 and from children born in 1993-1994 who had participated in a trial of pertussis vaccines. The annual incidence of culture-confirmed B. pertussis was 89-150 per 100,000 before introduction of acellular pertussis vaccines and has dropped to 17-26 per 100,000. The data suggest that unimmunised infants and children who have received only one dose of pertussis vaccine were provided some protection. The decline is most obvious from the second dose onwards and remained stable for 4-5 years after the third dose in the absence of any booster dose. The first signs of waning immunity were observed at 6-7 years of age in the trial cohort. The short-term benefits reflect high vaccination coverage and high initial efficacy. The full impact of the acellular pertussis vaccination programme in infants remains to be established.
Similar articles
-
Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group. Salmaso S, et al. Pediatrics. 2001 Nov;108(5):E81. doi: 10.1542/peds.108.5.e81. Pediatrics. 2001. PMID: 11694665 Clinical Trial.
-
Pertussis before and after the introduction of acellular pertussis vaccines in Finland.
Elomaa A, He Q, Minh NN, Mertsola J. Elomaa A, et al. Vaccine. 2009 Sep 4;27(40):5443-9. doi: 10.1016/j.vaccine.2009.07.010. Epub 2009 Jul 21. Vaccine. 2009. PMID: 19628060
-
Which strategy for pertussis vaccination today?
Girard DZ. Girard DZ. Paediatr Drugs. 2002;4(5):299-313. doi: 10.2165/00128072-200204050-00003. Paediatr Drugs. 2002. PMID: 11994035 Review.
-
Controlling pertussis: how can we do it? A focus on immunization.
Martinón-Torres F, Heininger U, Thomson A, Wirsing von König CH. Martinón-Torres F, et al. Expert Rev Vaccines. 2018 Apr;17(4):289-297. doi: 10.1080/14760584.2018.1445530. Epub 2018 Mar 12. Expert Rev Vaccines. 2018. PMID: 29482390 Review.
Cited by
-
Ennis DP, Cassidy JP, Mahon BP. Ennis DP, et al. Clin Diagn Lab Immunol. 2005 Mar;12(3):409-17. doi: 10.1128/CDLI.12.3.409-417.2005. Clin Diagn Lab Immunol. 2005. PMID: 15753254 Free PMC article.
-
Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM. Hallander HO, et al. J Clin Microbiol. 2005 Jun;43(6):2856-65. doi: 10.1128/JCM.43.6.2856-2865.2005. J Clin Microbiol. 2005. PMID: 15956409 Free PMC article.
-
Hara M, Okada K, Yamaguchi Y, Uno S, Otsuka Y, Shimanoe C, Nanri H, Horita M, Ozaki I, Nishida Y, Tanaka K. Hara M, et al. Clin Vaccine Immunol. 2013 Dec;20(12):1799-804. doi: 10.1128/CVI.00490-13. Epub 2013 Oct 9. Clin Vaccine Immunol. 2013. PMID: 24108779 Free PMC article. Clinical Trial.
-
Incidence of Pertussis in Anbar Province, West of Iraq, during 2009-2019.
Mohammed Abdullah E, Abdulla AM, Ali Khalil M, Ahmed Owaid H. Mohammed Abdullah E, et al. Arch Razi Inst. 2021 Dec 30;76(6):1687-1693. doi: 10.22092/ari.2021.356363.1829. eCollection 2021 Dec. Arch Razi Inst. 2021. PMID: 35546984 Free PMC article.
-
Advani A, Donnelly D, Hallander H. Advani A, et al. J Clin Microbiol. 2004 Jul;42(7):2890-7. doi: 10.1128/JCM.42.7.2890-2897.2004. J Clin Microbiol. 2004. PMID: 15243034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical